Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The delta opioid receptor (DOR) is a member of the opioid receptor family and a G protein-coupled receptor that primarily couples to inhibitory G proteins. Its endogenous ligands are enkephalins. It is widely distributed throughout the central nervous system and involved in analgesia (particularly chronic pain), mood regulation, and gastrointestinal motility. Selective delta agonists are being developed as potential analgesics with reduced side effects compared to mu-opioid agonists. Recent research highlights compartmentalized signaling from endosomes, contributing to prolonged analgesic effects during inflammatory states.
Gi/Go protein activation leading to inhibition of adenylyl cyclase, modulation of ion channels (K+ channel activation, Ca2+ channel inhibition), and activation of kinase cascades (ERK, Akt, JNKs, STAT3, p38 MAPK)
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Opioid Receptor Delta (DOR).